Pharma & Biotech
-
Herspiegel Consulting, Yardley BioPharma Advisor, Gets Capital Shot in the Arm from N.J. Investor
Herspiegel Consulting, the Yardley supplier of business guidance to the life-sciences and pharmaceutical industries, has received a “growth investment” from DFW Capital Partners in Teaneck, N.J. Founded in 2007, Herspiegel Consulting advises start-ups to Fortune 100 pharmaceutical clients on commercial projects. Its services address the details of product launch readiness, marketing, market access, medical affairs,…
-
Facing a Trio of Growth Strategies, OrthogenRx, Doylestown, Opts to Accept Acquisition Invitation
OrthogenRx Inc., which has been weighing a trio of options for its financial future, decided to accept a buyout offer from a medical equipment manufacturer in Georgia. John George covered the $160M transaction for the Philadelphia Business Journal. Founded in 2012, OrthogenRx specializes in therapies used to treat knee osteoarthritis pain. Its injectable treatments act…
-
Like Agar in a Petri Dish, State Funds to Spur Growth of Pennsylvania Biotechnology Center
State Senator Steve Santarsiero has secured a $1.5 million state grant to fund the growth and expansion of the Pennsylvania Biotechnology Center in Doylestown. The announcement came from a press report from Sen. Santarsiero. The Redevelopment Assistance Capital Program (RACP) provided the funding. “I’d like to thank Governor Wolf for supporting my request to dedicate RACP…
-
Revolutionary mRNA Research by Abington Biochemist Katalin Karikó Could Be Key to Solving Scores of Health Problems
The revolutionary mRNA research by Abington biochemist Katalin Karikó and her collaborator immunologist Drew Weissman could be the key to solving scores of health problems, writes Tim Smedley for the BBC. Their work went mostly unrecognized by the wider public before the pandemic. However, once the first COVID-19 vaccine was developed using their mRNA technology…
-
With Omicron Variant Now in the U.S., Could Exton-Based Immunome’s ‘Antibody Cocktail’ Be the Neutralizer?
Exton-based Immunome has submitted an application with the FDA to start human testing its “antibody cocktail” as a potential COVID-19 treatment, writes John George for the Philadelphia Business Journal. The biopharmaceutical company expects its experimental cocktail, known as IMM-BCP-01, to neutralize the newly discovered omicron variant. “Immunome designed its cocktail with multiple points of attack…
-
Optinose, Yardley, Looks to Raise $40M — Nothing to Sneeze at — to Expand Nasal Drug Delivery Device Line
Late last week, Optinose of Yardley closed its effort to raise $40 million through the sale of company stock. The capital infusion will expand its flagship nasal drug delivery products, reports John George for the Philadelphia Business Journal. The amount of the stock sale could grow by another $6 million if underwriters exercise their full…
-
Chester County Home to One of the Fastest-Growing Tech/Life Sciences Companies in North America
Deloitte has published its latest report of the 500 fastest-growing technology and life sciences companies in North America, and AscellaHealth in Berwyn is among them, reports Ryan Mulligan for the Philadelphia Business Journal. Deloitte’s 2021 Technology Fast 500 Rankings grades companies based on revenue growth from 2017-2020. Qualifying metrics were: minimum operating revenue of $50,000…
-
‘Smallpox’-Labeled Vials Found at Merck Lab in Upper Gwynedd Township
According to the Centers for Disease Control, a batch of vials labeled with “smallpox” were found in a freezer at a Merck facility in Upper Gwynedd Township and immediately quarantined, write Deanna Durante and Brian X. McCrone for NBC4 New York. It is not clear why the vials were there. Smallpox is a deadly disease…
-
Johnson & Johnson to Separate Into Two Businesses
Johnson & Johnson will separate into two public companies, writes John George for the Philadelphia Business Journal. One company will focus on consumer health products, while the other concentrates on pharmaceuticals and medical devices. Johnson & Johnson is based in New Brunswick, NJ. Its local sites include a manufacturing plant in Fort Washington (where Tylenol,…
-
Kannalife Sciences, Doylestown BioPharma Firm, Receives NIH Grant to Fund Pain Research
Kannalife Sciences, a subsidiary of Neuropathix, Inc., was awarded a $2.97 million grant from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke. John George covered the funding in the Philadelphia Business Journal. Kannalife is housed at The Pennsylvania Biotechnology Center of Bucks County, as is its parent. The three-year grant is…
-
CleanSpace Modular, Doylestown Producer of Pharma Environments, Sees 340 Percent Growth in Two Years
CleanSpace Modular, centered in Doylestown, is now the fastest-growing company in the Greater Philadelphia area. Its product line — “clean rooms” that filter out harmful, airborne particles — has become essential to healthcare systems and pharmaceutical companies nationwide. Lisa Dukart sifted through the details of its success for the Philadelphia Business Journal. The company manufactures…
-
Tim Block, President of Pennsylvania Biotech Center, to Scale Back, Be Replaced Next Year by Current EVP, COO
Tim Block announced his July 2022 plans to step down as president of the Pennsylvania Biotechnology Center in Doylestown. John George covered the professional move for the Philadelphia Business Journal. Block’s replacement is Lou Kassa, present executive vice president and chief operating officer. The announcement of the shift for Block also covered his role as…
-
Stockholder Approval of Strongbridge Biopharma Merger Takes It Out of Bucks County… And Pennsylvania, Too
The recent shareholder decision regarding the merger between Strongbridge Biopharma and Xeris Pharmaceuticals was a nearly unanimous yes. John George covered the implications of that vote for the Philadelphia Business Journal. More than 99 percent of the votes cast — representing 67 percent of shares outstanding and eligible — favored the transaction. Both parties expect…
-
NEXGEL, Hydrogel Provider in Langhorne, Appoints New CFO, Adam Drapczuk
NEXGEL, a Langhorne-based medical supply manufacturer, has named Adam Drapczuk as Chief Financial Officer. The firm produces a hydrogel that serves healthcare and consumer users. In the healthcare industry that NEXGEL serves, hydrogels are commonly used for skin patches that can be safely worn for extended periods. The compound’s consumer applications include diapers, contact lenses,…
-
FDA Cites ‘Breakthrough’ Helius Medical Technologies Device for Helping Stroke and MS Patients Walk More Confidently
The U.S. Food and Drug Administration (FDA) recognized a device produced by Newtown-based neurotech company Helius Medical Technologies, Inc. The solution, a portable neuromodulator stimulator (PoNS), enables patients with walking difficulties to steady their gait. Its market includes patients who have had a stroke or have MS. Although not a sole answer to mobility issues,…
-
Doylestown’s Neuropathix, Inc., Gains 20-Year Industry Veteran in Its Fight Against Opioid and Pain Addiction
Neuropathix, Inc., a pain management life sciences company in Doylestown, has appointed pharmaceutical industry veteran Michael Ropacki, PhD, to its scientific advisory board. Ropacki is a globally recognized executive with over 20 years’ clinical development experience. Among numerous professional affiliations, he is also a National Institute of Health advisor. “I am extremely excited and grateful…
-
After Courting Many, Strongbridge Biopharma of Trevose Chose to Dance with a Chicago Pharmaceutical Firm
Like a high school boy searching for a prom date, Strongbridge Biopharma talked to a number of potential acquisition partners before finally getting the ‘yes’ it sought. John George covered the company’s search in the Philadelphia Business Journal. Cutting to the chase, Strongbridge Biopharma has negotiated its acquisition by Xeris Pharmaceuticals. The two firms executed…
-
Doylestown Med-Tech Company Boosts Speed and Accuracy of Clinical Trial Data Collection
assisTek, Doylestown provider of clinical trial tech solutions, released the next generation of its electronic clinical outcome assessment (eCOA) platform. Fully cloud-based, the updated platform includes enhancements for patients, clinical teams, sponsors, and contract research organizations. Its functionality aligns well with industry best practices for collection of clinical outcomes. “At assisTek, we have a 25-year-long commitment to leadership in our field,” said Cindy…
Founding Partners
Advertisement
Affiliate Partners
